Skip to main content
SpringerLink
Log in

Pharmakologische Therapie der Alzheimer-Demenz

Aktueller Stand und Perspektiven

Drug treatment of Alzheimer’s dementia

Status quo and perspectives

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Alzheimer-Demenz ist eine neurodegenerative Erkrankung des zentralen Nervensystems. Sie ist charakterisiert durch progrediente Beeinträchtigungen des Gedächtnisses sowie weiterer kognitiver Funktionen und einen zunehmenden Verlust der Autonomie im Alltag. Dieser Review gibt einen Überblick über den Goldstandard der aktuellen (symptomatischen) pharmakologischen Therapie der Alzheimer-Demenz und über Besonderheiten im Kontext von neuropsychiatrischen Begleitsymptomen und multimorbiden Patienten. Zudem bietet er einen Ausblick auf aktuell in der Entwicklung befindliche, potenziell kausal wirksame Medikamente.

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease of the central nervous system. AD is characterized by progressive impairments of memory as well as other cognitive functions and an increasing loss of autonomy in everyday life. This review article provides an overview of the current state-of-the-art (symptomatic) pharmacological treatment of Alzheimer’s disease, specifics in the context of concomitant neuropsychiatric symptoms in multimorbid patients, and drugs currently under development that have a potentially causal (disease modifying) effect are also mentioned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 1:CD5593. https://doi.org/10.1002/14651858.CD005593

    Article  Google Scholar 

  2. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 1:CD3120. https://doi.org/10.1002/14651858.CD003120.pub3

    Article  Google Scholar 

  3. Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr Opin Neurol 25(6):708–714. https://doi.org/10.1097/WCO.0b013e32835a3432

    Article  CAS  PubMed  Google Scholar 

  4. Cacabelos R, Martínez R, Fernández-Novoa L, Carril JC, Lombardi V, Carrera I, Corzo L, Tellado I, Leszek J, McKay A, Takeda M (2012) Genomics of dementia: aPOE- and CYP2D6-related Pharmacogenetics. Int J Alzheimers Dis 2012:518901. https://doi.org/10.1155/2012/518901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14(7):399–415. https://doi.org/10.1038/s41582-018-0013-z

    Article  CAS  PubMed  Google Scholar 

  6. Cummings J, Aisen PS, Dubois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P (2016) Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther 8:39. https://doi.org/10.1186/s13195-016-0207-9

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K (2017) Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (N Y) 3(3):367–384. https://doi.org/10.1016/j.trci.2017.05.002

    Article  Google Scholar 

  8. DGPPN, DGN (2017) S3-Leitlinie Demenzen. Interdisziplinäre S3-Praxisleitlinien. Springer, Berlin, Heidelberg

    Book  Google Scholar 

  9. DGPPN, Deutsche Gesellschaft f. Neurologie, Springer-Verlag GmbH (2017) S3-Leitlinie Demenzen. Interdisziplinäre S3-Praxisleitlinien. Springer, Berlin, Heidelberg

    Book  Google Scholar 

  10. Doblhammer G, Fink A, Fritze T, Nerius M (2018) 2. Demographische Entwicklung und Epidemiologie von Demenzerkrankungen. In: Jessen F (Hrsg) Handbuch Alzheimer-Krankheit. De Gruyter, Berlin, Boston, S 13–34

    Chapter  Google Scholar 

  11. Fernández-Martínez M, Castro J, Molano A, Zarranz JJ, Rodrigo RM, Ortega R (2008) Prevalence of neuropsychiatric symptoms in Alzheimer’s disease and vascular dementia. Curr Alzheimer Res 5(1):61–69

    Article  Google Scholar 

  12. Förstl H (Hrsg) (2011) Demenzen in Theorie und, 3. Aufl. Springer, Berlin, Heidelberg

    Google Scholar 

  13. Gutzmann H (2014) Aktuelle Therapieoptionen bei Demenz. DNP 15(11):54–63. https://doi.org/10.1007/s15202-014-0812-z

    Article  Google Scholar 

  14. Hausner L, Frölich L (2019) Medikamentöse Therapie der Alzheimer-Demenz mit Antidementiva. Dtsch Med Wochenschr 144(3):156–160. https://doi.org/10.1055/a-0658-6720

    Article  CAS  PubMed  Google Scholar 

  15. Hofmann W (2017) Demenz und internistische Komorbidität. Internist (Berl) 58(2):105–116. https://doi.org/10.1007/s00108-016-0182-z

    Article  CAS  Google Scholar 

  16. Hölscher C (2018) Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.040

    Article  PubMed  PubMed Central  Google Scholar 

  17. Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107(31–32):543–551. https://doi.org/10.3238/arztebl.2010.0543

    Article  PubMed  PubMed Central  Google Scholar 

  18. Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E (2018) Trial of Solanezumab for mild dementia Due to Alzheimer’s disease. N Engl J Med 378(4):321–330. https://doi.org/10.1056/NEJMoa1705971

    Article  CAS  PubMed  Google Scholar 

  19. Howard R, McShane R, Lindesay J et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366(10):893–903. https://doi.org/10.1056/NEJMoa1106668

    Article  CAS  PubMed  Google Scholar 

  20. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562. https://doi.org/10.1016/j.jalz.2018.02.018

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun 7(1):22. https://doi.org/10.1186/s40478-019-0664-z

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kraft JW (2017) Medikamentöse Therapie demenzieller Erkrankungen. Internist (Berl) 58(2):117–124. https://doi.org/10.1007/s00108-016-0180-1

    Article  CAS  Google Scholar 

  23. Laver K, Dyer S, Whitehead C, Clemson L, Crotty M (2016) Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open 6(4):e10767. https://doi.org/10.1136/bmjopen-2015-010767

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Baillieres Clin Neurol 54(11 Suppl 5):4–9

    Google Scholar 

  25. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 9(7):702–716. https://doi.org/10.1016/S1474-4422(10)70119-8

    Article  CAS  PubMed  Google Scholar 

  26. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Primers 1:15056. https://doi.org/10.1038/nrdp.2015.56

    Article  PubMed  Google Scholar 

  27. Müller P, Schmicker M, Müller NG (2017) Präventionsstrategien gegen Demenz. Z Gerontol Geriatr 50(Suppl 2):89–95. https://doi.org/10.1007/s00391-017-1202-x

    Article  PubMed  Google Scholar 

  28. Müller P, Taubert M, Müller NG (2019) Physical exercise as personalized medicine for dementia prevention? Front Physiol 11:1–5. https://doi.org/10.3389/fphys.2019.00672

    Article  Google Scholar 

  29. Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum K‑U, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H (2018) Amyloid blood biomarker detects Alzheimer’s disease. Embo Mol Med. https://doi.org/10.15252/emmm.201708763

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nabers A, Hafermann H, Wiltfang J, Gerwert K (2019) Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer’s disease. Alzheimers Dement (amst) 11:257–263. https://doi.org/10.1016/j.dadm.2019.01.008

    Article  Google Scholar 

  31. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li Q‑X, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554(7691):249–254. https://doi.org/10.1038/nature25456

    Article  CAS  PubMed  Google Scholar 

  32. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4):448–452. https://doi.org/10.1038/nm840

    Article  CAS  PubMed  Google Scholar 

  33. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13(8):788–794. https://doi.org/10.1016/S1474-4422(14)70136-X

    Article  Google Scholar 

  34. Peters O, Grimmer T, Häussermann P, Sieber CC (2018) 8. Medikamentöse Therapie. In: Jessen F (Hrsg) Handbuch Alzheimer-Krankheit. De Gruyter, Berlin, Boston, S 427–484

    Chapter  Google Scholar 

  35. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5(1):83–89

    Article  CAS  Google Scholar 

  36. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 275(3):251–283. https://doi.org/10.1111/joim.12191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tai J, Liu W, Li Y, Li L, Hölscher C (2018) Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Brain Res 1678:64–74. https://doi.org/10.1016/j.brainres.2017.10.012

    Article  CAS  PubMed  Google Scholar 

  38. Wehling M, Throm C (2015) Polypharmazie im Alter – klug entscheiden mit dem FORTA-Prinzip. Dtsch Med Wochenschr 140(18):1378–1382. https://doi.org/10.1055/s-0041-103205

    Article  PubMed  Google Scholar 

  39. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15(4):555–569

    Article  CAS  Google Scholar 

  40. Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15(5):455–532. https://doi.org/10.1016/S1474-4422(16)00062-4

    Article  PubMed  Google Scholar 

  41. Zhao Q‑F, Tan L, Wang H‑F, Jiang T, Tan M‑S, Tan L, Xu W, Li J‑Q, Wang J, Lai T‑J, Yu J‑T (2016) The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord 190:264–271. https://doi.org/10.1016/j.jad.2015.09.069

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AG Neuroprotektion, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Leipziger Str. 44, 39120, Magdeburg, Deutschland

    P. Müller & N. G. Müller

  2. Institut für Pharmakologie und Toxikologie, Otto-von-Guericke-Universität, Magdeburg, Deutschland

    M. Fendt

  3. Center for Behavioural Brain Sciences (CBBS), Magdeburg, Deutschland

    M. Fendt & N. G. Müller

  4. Universitätsklinik für Neurologie, Otto-von-Guericke-Universität, Magdeburg, Deutschland

    N. G. Müller

Authors
  1. P. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Fendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. G. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Müller.

Ethics declarations

Interessenkonflikt

P. Müller, M. Fendt und N.G. Müller geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

M. Wehling, Mannheim

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müller, P., Fendt, M. & Müller, N.G. Pharmakologische Therapie der Alzheimer-Demenz. Internist 60, 761–768 (2019). https://doi.org/10.1007/s00108-019-0625-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-0625-4

Schlüsselwörter

Keywords

Search

Navigation